Navigation Links
An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes

, as assessed by measurement of S(-) or R(+) warfarin enantiomers, or pharmacodynamics (as assessed by measurement of prothrombin INR) of a single dose of warfarin. Because S(-) warfarin is primarily metabolized by CYP2C9, these data also support the conclusion that sitagliptin is not a CYP2C9 inhibitor. Oral Contraceptives: Co-administration with sitagliptin did not meaningfully alter the steady-state pharmacokinetics of norethindrone or ethinyl estradiol. Effects of Other Drugs on Sitagliptin Clinical data described below suggest that sitagliptin is not susceptible to clinically meaningful interactions by co-administered medications: Metformin: Co-administration of multiple twice-daily doses of metformin with sitagliptin did not meaningfully alter the pharmacokinetics of sitagliptin in patients with type 2 diabetes. Cyclosporine: A study was conducted to assess the effect of cyclosporine, a potent inhibitor of p-glycoprotein, on the pharmacokinetics of sitagliptin. Co-administration of a single 100 mg oral dose of JANUVIA and a single 600 mg oral dose of cyclosporine increased the AUC and Cmax of sitagliptin by approximately 29% and 68%, respectively. These modest changes in sitagliptin pharmacokinetics were not considered to be clinically meaningful. The renal clearance of sitagliptin was also not meaningfully altered. Therefore, meaningful interactions would not be expected with other p-glycoprotein inhibitors. 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility A two-year carcinogenicity study was conducted in male and female rats given oral doses of sitagliptin of 50, 150, and 500 mg/kg/day. There was an increased incidence of combined liver adenoma/carcinoma in males and females and of liver carcinoma in females at 500 mg/kg. This dose results in exposures approximately 60 times the human exposure at the maximum recommended daily adult human dose (MRHD) of
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:1/15/2014)... SAN ANTONIO , Jan. 15, 2014 Most ... take, according to a recent online survey* sponsored by ... among the National Osteoporosis Foundation online support community, ... to take medication that comes in a form other ...
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and ... be able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of the ... steadfastly remains one of the most litigious industry ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Fla., April 20, 2011 Legal-Bay LLC, through its ... making a substantial commitment to plaintiffs in need of ... Cases.  Legal-Bay is already an industry leader; however they ... funding areas.  Recently the company announced that they have ...
... 2011 The Society of ... taking a leading role in measuring and assessing radiation ... and reduction of skin dosage; and promoting the safety ... this month in the Journal of Vascular and Interventional ...
Cached Medicine Technology:Legal-Bay LLC Announces Opening of Jones Act Lawsuit Funding Division 2Society of Interventional Radiology Addresses Radiation Safety, Advances Best Practices 2Society of Interventional Radiology Addresses Radiation Safety, Advances Best Practices 3Society of Interventional Radiology Addresses Radiation Safety, Advances Best Practices 4Society of Interventional Radiology Addresses Radiation Safety, Advances Best Practices 5
(Date:7/11/2014)... adults who screened positive for a history of hazardous ... than 50 percent after receiving mobile phone text messages ... a study published online yesterday in Annals of ... for Young Adult Emergency Department Patients: A Randomized Clinical ... than 50,000 adults ages 18 to 24 visit ERs ...
(Date:7/11/2014)... Recently, Fadhits.com, the distinguished wedding dress manufacturer and retailer, has ... To bring more benefits to worldwide clients in this great ... for these brand new items. Clients can enjoy thwe special ... says gladly, “We are happy to announce such a promotion. ... new and old customers and strengthen our relationship with them. ...
(Date:7/11/2014)... Hills, CA (PRWEB) July 11, 2014 Bedros ... marketing expert; a title he’s earned by founding the fast-selling ... professionals on marketing their businesses. He works with successful boot ... blog post on the traits of the most successful ... earners share three important qualities. , “I’ve worked with and ...
(Date:7/11/2014)... H.E.A.R Me Out Listens to Needs of Hearing ... provide comprehensive information and services available to Colorado’s hearing ... with hearing loss, this organization is the first of ... local and state resources that aims to give new ... Me Out and its website was founded by Colorado ...
(Date:7/11/2014)... is history in much of the world, but remains ... vaccinated children an extra dose of inactivated polio vaccine ... infectious disease, a new study suggests. Although the ... as a year after vaccination. Vaccinated children and adults ... of the disease, according to background information in the ...
Breaking Medicine News(10 mins):Health News:Text message medicine: Texts from the ER can reduce binge drinking 2Health News:Promotion for Kids Prom Dresses Now Provided at Fadhits.com 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 3Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 2Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 3Health News:Researchers Assess New Way to Boost Polio Immunity 2
... study has found that among women who have never ... increased risk of developing ovarian cancer compared with women ... issue of CANCER , a peer-reviewed journal of ... may contribute to the development of ovarian cancer through ...
... is urging women to continue waging a battle against the Food ... hormones. , ... Potomac, MD (PRWEB) January 2, 2009 ... health practitioner, is urging women to continue waging a battle against ...
... The National Parkinson Foundation (NPF) awarded ... new evidence-based interventions aimed at preventing falls in ... grants to five different research projects at NPF ... and the United States. NPF supports a ...
... asks you to help save lives by donating blood ... being held on Tuesday, January 6th from 2 pm ... Gloucester City, New Jersey. To make an immediate ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081216/DC52619LOGO ) Goldglantz suffered 3rd ...
... while performing winter task , , FRIDAY, Jan. 2 (HealthDay ... can be physically challenging and dangerous work, so you ... the American Academy of Orthopaedic Surgeons (AAOS). , ... U.S. hospital emergency rooms, doctors, offices, clinics and other ...
... key to understanding, and perhaps killing, dormant ovarian cancer ... years later, researchers at The University of Texas M. ... Journal of Clinical Investigation . , The team found ... a switch for autophagy, or self-cannibalization, in ovarian cancer ...
Cached Medicine News:Health News:Study links obesity to elevated risk of ovarian cancer 2Health News:Susan Lark, MD Urges Women to Fight for Their Right to Use Bioidentical Hormones 2Health News:Susan Lark, MD Urges Women to Fight for Their Right to Use Bioidentical Hormones 3Health News:The National Parkinson Foundation Awards Five Grants for the Falls Prevention Initiative 2Health News:The National Parkinson Foundation Awards Five Grants for the Falls Prevention Initiative 3Health News:Blood Drive Held in Honor of Gloucester City Resident - Evan Goldglantz 2Health News:Shovel Snow Safely 2Health News:Dormant cancer cells rely on cellular self-cannibalization to survive 2
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Inoculum Broth with Calcium Chloride and Phytone....
...
Medicine Products: